Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022 07:00 ET
|
Cullinan Oncology, Inc.
Initiated pivotal study for zipalertinib (CLN-081/TAS6417) Increased ownership in MICA subsidiary, which holds worldwide rights to CLN-619, from 54% to 92% Continued enrollment in CLN-049...
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
November 02, 2022 08:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan Oncology”), a biopharmaceutical company focused on modality-agnostic targeted oncology for...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022 17:23 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with...
Cullinan Oncology to Participate in Upcoming Investor Conferences
November 01, 2022 07:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology for...
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
October 25, 2022 07:00 ET
|
Cullinan Oncology, Inc.
Cullinan increases ownership in MICA subsidiary from 54% to 92% through share purchase from existing financial investors The ongoing Phase I clinical trial for CLN-619 remains on track to report...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022 16:50 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted...
Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
September 07, 2022 08:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2022 17:27 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted...
Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
August 15, 2022 16:57 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 10, 2022 07:00 ET
|
Cullinan Oncology, Inc.
Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Presented updated Phase 1/2a data for CLN-081 at the 100mg BID dose showing...